908 Devices

908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

908 Devices reports revenue growth, eyes biopharma sector improvement

908 Devices showed solid financial performance in 2022, with revenue growth and strategic expansions.
While facing challenges like macro headwinds and lower REBEL placements, the company is focused on innovation.
Opportunities lie in biopharma sector improvement, product utilization rates, and unit growth expectations.
Maintaining a strong cash position and disciplined capital deployment are key strengths for future growth.

908 Devices reports revenue growth and strategic partnerships driving innovation

908 Devices delivered solid performance in Q1 2023, marked by revenue growth, strong recurring revenue, and strategic partnerships driving innovation and market expansion.
While facing challenges in operating expenses and gross margins, the company's focus on handheld devices, recurring revenues, and cost management positions it for future success.
With a robust cash position, ongoing product launches, and a diverse sales funnel, 908 Devices is poised to capitalize on opportunities in the biopharma and cell therapy markets.

908 Devices reports revenue growth and strategic focus for growth

908 Devices showcased revenue growth and strong performance in key product segments. While managing expenses prudently and focusing on key markets, the company faces challenges with a net loss and the need for additional handheld unit growth. Opportunities lie in upcoming product launches, government contracts, and pipeline updates.

908 Devices reports Q3 revenue growth, eyes strong 2024 prospects

908 Devices showed solid performance in Q3 2023, driven by growth in handheld devices and strategic collaborations. Despite challenges in the bio-processing space, the company remains optimistic about future growth and product development.
With a strong cash position, no debt, and a focus on returning to high growth rates, 908 Devices is poised for success in 2024. The company's emphasis on process analytical technology tools and expanding market offerings presents promising opportunities for the future.
While facing challenges in revenue expectations and utilization rates, 908 Devices is actively addressing these issues to drive sustainable growth. The company's commitment to innovation and market expansion positions them well for long-term success.

908 Devices reports strong Q4 performance and optimistic outlook for 2024

908 Devices showed revenue growth and improved net loss in Q4 2023, with a positive outlook for 2024.
The company's strong cash position, successful partnerships, and product confidence are key strengths.
Challenges include margin pressures from pricing adjustments and increased spending.
Opportunities lie in revenue growth guidance, customer interest in new products, and market expansion plans.

908 Devices reports solid Q1 performance, eyes growth opportunities

908 Devices had a strong start in Q1 2024, driven by revenue growth and RedWave acquisition.
Challenges include net loss, declining desktop product revenue, and cost management.
Opportunities lie in engagement with cell therapy accounts, revenue synergies, and cash flow improvement.
Strategic fit of RedWave acquisition offers growth potential and cost synergies in the long term.

908 Devices reports solid Q2 earnings, eyes growth through diversification

908 Devices demonstrated strong revenue growth in Q2 2024, driven by robust performance in handheld forensics devices.
While facing challenges in desktop product revenue, the company's focus on recurring revenue and market expansion bodes well for future prospects.
Strategic adjustments and continued emphasis on operational excellence position 908 Devices for sustained success in diverse markets.

908 Devices faces revenue challenges but pursues growth opportunities

908 Devices reported mixed financial performance in Q3 2024, with revenue growth but falling short of expectations, leading to a net loss.
The company is taking steps to optimize operations, identify growth drivers, and drive margin expansion for future success.
Challenges include revenue guidance adjustments, competitive pressures, and financial losses, which require strategic responses.
Opportunities lie in product innovation, strategic partnerships, and effective implementation of sales strategies to drive growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, continues to equip its life science customers with actionable intelligence at the point-of-need, enabling them to drive advancements in biotherapeutic development.

908 Devices Records Strong Momentum in Life Sciences Sector

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the availability of a downloadable target pack for the MX908® to enable identification of toxic pesticides.

908 Devices Launches Pesticide Identification Capability to Thwart Illegal Marijuana Growing Operations

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022.

908 Devices to Report Third Quarter 2022 Financial Results on November 14, 2022

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, announced that its collaboration with CPI is demonstrating the value of at-line cell culture media analysis to inform feeding strategies for improved cell growth in bioprocessing applications.

908 Devices and CPI Improve mAbs Cell Culture Outcomes Using At-line Media Analysis

908 Devices Inc. (NASDAQ:MASS ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Kelly Gura - Investor Relations Kevin Knopp - Chief Executive Officer & Co-Founder Joe Griffith - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Max Masucci - Cowen Operator Hello, thank you for standing by. And welcome to the 908 Devices' Second Quarter 2022 Financial Results Conference Call.

908 Devices Inc. (MASS) CEO Kevin Knopp on Q2 2022 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended June 30, 2022. “We are pleased with our first half 2022 performance, in which our revenue grew 40%, including desktop revenue growth of 52%. I am encouraged by the continued enthusiasm we are seeing across our end markets for real-time analysis at the point-of-need,” said Kevin J

908 Devices Reports Second Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announces that it has completed the acquisition of privately-held TRACE Analytics GmbH, based in Braunschweig, Germany, a provider of on-line analysis and sampling systems for biotech applications. 908 Devices expects the acquired technology to enable its mass spec devices as on-line bioprocess monitors. Founded in 2003, TRACE Analy

908 Devices Acquires TRACE Analytics, Enabling On-line Bioanalytics

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will be participating in the upcoming Canaccord Genuity 42nd Annual Growth Conference. 908 Devices' management is scheduled to host a Fireside Chat on Wednesday, August 10th at 2:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the com

908 Devices to Participate in the Canaccord Genuity 42nd Annual Growth Conference

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the second quarter 2022 before market open on Tuesday, August 9, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company

908 Devices to Report Second Quarter 2022 Financial Results on August 9, 2022

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, is showcasing the use of its high-pressure mass spectrometry and microfluidics separation technologies in twelve presentations at the 70th American Society for Mass Spectrometry (ASMS) Conference June 5-9 in Minneapolis. The presentations, which include one oral and eleven posters, highlight technology to accelerate drug development workf

908 Devices Showcases Technology for Accelerating Mass Spec Workflows in Presentations at ASMS

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will be participating in the upcoming William Blair 42nd Annual Growth Stock Conference. 908 Devices' management is scheduled to present on Thursday, June 9th, at 8:00 a.m. Central Time / 9:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section

908 Devices to Participate in the William Blair 42nd Annual Growth Stock Conference

908 Devices, Inc. (NASDAQ:MASS ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Kelly Gura - Investor Relations Kevin Knopp - Chief Executive Officer & Co-Founder Joe Griffith - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Dan Arias - Stifel Brian Weinstein - William Blair Operator Good morning and thank you for standing by. Welcome to the 908 Devices' First Quarter 2022 Financial Results Conference Call.

908 Devices, Inc. (MASS) CEO Kevin Knopp on Q1 2022 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended March 31, 2022. “We had a strong start to the year with revenue growing 50% over the prior year period. We made tangible progress against our goals as we continued to enable our customers with rapid chemical and biochemical analysis when and where they need it,” said Kevin J. Kno

908 Devices Reports First Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced updates to its MX908 handheld mass spec device, adding new capabilities to streamline workflows and improve field safety for first responders. The device will now include enhanced Bluetooth features with remote applications for iPhone mobile devices, as well as a broader range of drugs, including fentanyl analogs and

908 Devices Advances MX908 Handheld Device Capabilities

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, is partnering with the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC), an academic-industry research consortium dedicated to implementing bioengineering innovations that enhance the development and manufacture of complex biotherapeutics. As part of this mission, researchers are now utilizing 908 Devices' REBEL™ analyzer to improve pr

908 Devices Partners with Key Biomanufacturing Innovation Center

BOSTON--(BUSINESS WIRE)--908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, is collaborating with UK-based, deep-tech innovation organization CPI on a project to optimize mammalian cell culture media and feeding strategies to improve growth, protein titer and protein quality attributes. CPI researchers are utilizing 908 Devices' REBEL™ desktop device for at-line cell culture media analysis, helping to identify and then con

908 Devices and CPI Team on Cell Culture Media Optimization for Improved Process Control in Bioprocessing Applications

BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 10, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company we

908 Devices to Report First Quarter Financial Results on May 10, 2022

The niche healthcare company delivers a pair of convincing beats in its fourth quarter results.

Why 908 Devices Stock Rocketed 15% Higher Today

908 Devices Inc's (NASDAQ: MASS) Q4 FY21 revenue increased 177% Y/Y to $15.8 million, beating the consensus of $15.11 million. The increase was primarily driven by handheld revenue that increased 262%, mainly related to shipments to the US Army under the multi-year purchase order.

908 Devices Reports Narrower Quarterly Loss As Handheld Devices Boost Q4 Sales

908 Devices Inc.'s (MASS) CEO Kevin Knopp on Q4 2021 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter and full year ended December 31, 2021. “2021 was a pivotal year for 908 Devices. We grew revenue 57% over the prior year and demonstrated operational excellence during our first year as a public company. I am so proud of our team's continuous execution against our stated goals,” said K

908 Devices Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Revenue Outlook

Lithium Americas Corp

Petco Health and Wellness

The number of companies posting quarterly results drops below 500 next week, as the current earnings-reporting season winds down.

Earnings Previews: Dick's, Lithium Americas, 908 Devices, Petco

Repligen

BOSTON--(BUSINESS WIRE)--908 Devices has appointed Tony J. Hunt, President and CEO of Repligen Corporation to serve on its Board of Directors effective immediately.

908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, March 7, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of

908 Devices to Report Fourth Quarter and Full Year 2021 Financial Results on March 7, 2022

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2021. Preliminary unaudited revenue for the fourth quarter of 2021 is expected to be at least $15.1 million, compared to $5.7 million in the fourth quarter of 2020, reflecting growth of at least 165%. Preliminary unaudited revenue f

News for 908 Devices Stock (MASS)